Comparison · NCT00623623-sae
Tenecteplase (Group A) vs Primary PCI (Group B): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tenecteplase (Group A) vs Primary PCI (Group B): serious adverse events. Trial comparisons, record NCT00623623-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00623623-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.154 | 0.132 | 0.178 | wilson | |
| Risk in group 2 | 0.173 | 0.15 | 0.198 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0191 | -0.0525 | 0.0142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.889 | 0.725 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 0.869 | 0.681 | 1.11 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Tenecteplase (Group A) than on Primary PCI (Group B) | 52.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tenecteplase (Group A) | Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment) | 146 | 949 | EG000 |
| Group 2 | Primary PCI (Group B) | Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.~Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines. | 164 | 948 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first drug administration until end of tiral, up to 30 days
Source ClinicalTrials.gov
Trial
- Title
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- NCT number
- NCT00623623
- Phases
- PHASE3
- Conditions
- Myocardial Infarction
- Interventions
- primary PCI, enoxaparin, catheterisation, tenecteplase, clopidogrel
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2019-08-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00623623?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00623623-sae